Resume (Education and Working Experience)

Education：

1. 2000.09 – 2004.06 BSc in Science of Chinese Materia Medica, Guangzhou University of Chinese Medicine, China.
2. 2004.09 – 2007.06 MPhil in Science of Chinese Materia Medica, School of Chinese Medicine, Guangzhou University of Chinese Medicine, China.
3. 2001.01 – 2013.07 PhD in Chinese Medicine, School of Chinese Medicine, The Chinese University of Hong Kong.

Working Experience：

1. 2007.04 – 2010.12    Research Assistant, School of Chinese medicine, Faculty of Medicine, The Chinese University of Hong Kong
2. 2013.08 – 2017.07 Postdoctoral Fellow, School of Chinese medicine, The Chinese University of Hong Kong.
3. 2017.08 – 2022.10 Research Assistant Professor, School of Chinese medicine, Faculty of Medicine, The Chinese University of Hong Kong.
4. 2022.11 – present Assistant Professor, School of Chinese medicine, Faculty of Medicine, The Chinese University of Hong Kong.

Research Interest

Awards

1. Obtained Qihuang Young Scholar Funding by National Administration of Traditional Chinese Medicine

Selected Publications

1. Zhu H, Tian Y, Chen H, Qian Y, Li J, Niu D, Zhao W, Zhang X, Tang T, Li H, Xian YF*, Sun D^*, Jin C^*. Targeting DNA Damage Response Pathways in Tumor Drug Resistance: Mechanisms, Clinical Implications, and Future Directions. Drug Resistance Updates 2025;83:101287. (IF: 21.7)
2. Zhong M, Xu QQ, Huang MQ, Zhan RT, Huang XQ, Yang W, Lin ZX, Xian YF*. Rhynchophylline alleviates cognitive deficits in multiple transgenic mouse models of Alzheimer's disease via modulating neuropathology and gut microbiota. Acta Pharmacologica Sinica 2025;46(7):1813-1833. (IF: 8.4)
3. Zhang J, Wu YL, Xu HX, Tian Y, Lin ZX*, Xian YF*. Chinese herbal medicine for the treatment of intestinal cancer: preclinical studies and potential clinical applications. Molecular Cancer 2024;23(1):217. (IF: 33.9)
4. Wu YL, Zhang J, Xu HX, Tian Y, Cho WCS, Lin ZX*, Xian YF*. 20(S)-Ginsenoside Rh2 overcomes gemcitabine resistance in pancreatic cancer by inhibiting LAMC2-Modulated ABC transporters. Journal of Advanced Research 2024;73:743-760. (IF: 13)
5. Qu C, Xu QQ, Yang W, Zhong M, Yuan Q, Xian YF*, Lin ZX*. Gut Dysbiosis Aggravates Cognitive Deficits, Amyloid Pathology and Lipid Metabolism Dysregulation in a Transgenic Mouse Model of Alzheimer’s Disease. Journal of Pharmaceutical Analysis 2023;13:1526-1547. (IF: 8.9)
6. Xu QQ, Su ZR, Yang W, Zhong M, Xian YF*, Lin ZX*. Patchouli Alcohol Attenuates the Cognitive Deficits in a Transgenic Mouse Model of Alzheimer’s Disease via Modulating Neuropathology and Gut Microbiota through Suppressing C/EBPβ/AEP Pathway. Journal of Neuroinflammation 2023;20:19. (IF: 10.1)
7. Zhang J, Xu HX, Cho WCS, Cheuk W, Li Y, Huang QH, Yang W, Xian YF*, Lin ZX*. Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the Nrf2-mediated mechanism. Journal of Experimental & Clinical Cancer Research 2022;41(1):90. (IF: 12.8)
8. Huang QH, Zhang J, Cho WCS, Huang Y, Yang W, Zuo Z, Xian YF*, Lin ZX. Brusatol suppresses the tumor growth and metastasis of colorectal cancer via upregulating ARRDC4 expression through modulating PI3K/YAP1/TAZ pathway. Phytomedicine 2022;109:154567. (IF: 8.3)
9. Qu C, Li QP, Su ZR, Ip SP, Yuan QJ, Xie YL, Xu QQ, Yang W, Huang YF, Xian YF*, Lin ZX*. Nano-honokiol ameliorates the cognitive deficits in TgCRND8 mice of Alzheimer’s disease via inhibiting neuropathology and modulating gut microbiota. Journal of Advanced Research 2021;35:231-43. (IF: 13)
10. Xian Y, Zhang J, Bian Z, Zhou H, Zhang Z, Lin Z*, Xu H*. Bioactive Natural Compounds against Human Coronaviruses: A Review and Perspective. Acta Pharmaceutica Sinica B 2020;10(7):1163-1174. (IF: 14.6)

* Corresponding Author

Grants:

Principle Investigator (PI):

1. PI, Efficacy and Safety of a Novel Chinese Medicine Formula for Allergic Rhinitis: a Randomized, Double-blinded, Placebo-controlled Trial, HMRF, HK$1,500,000
2. PI, Evaluating the Efficacy and Safety of Modified Qing-Zao-Jiu-Fei Decoction on Pneumoconiosis Patients: A Randomized, Double-blinded, Placebo-Controlled Trial, PCFB, HK$ 2,841,800
3. PI, 中醫藥防治常見疾病之推廣計劃, CMDF, HK$ 739,316
4. PI, Probing Rhynchophylline as a Novel Alzheimer’s Disease Agent: Targeting Galectin-3/C/EBPβ/δ-Secretase Pathway, NSFC, RMB 300,000.
5. PI, Development of A Chinese Medicine Formula for Treatment of Ketamine-Cognitive Deficits and Cystitis: Preclinical Evaluations on Its Efficacy, Safety and Molecular Mechanisms, Beat Drugs Fund, HK$ 1,610,112.
6. PI, Development of Modified Qing-Zao-Jiu-Fei Decoction as a Novel Agent for Pneumoconiosis: Preclinical Evaluation on Its Efficacy, Safety and Molecular Mechanisms, PCFB, HK$ 1,205,563.
7. PI, Potential Herb-Drug Interactions between Androgenic Chinese Herbal Medicines and Androgen Receptor Antagonists (Abiraterone acetate and Enzalutamide) - a Preclinical Evaluation, HMRF, HK$964,800.
8. PI, Modified Tianma-Gouteng Yin as a Novel Alzheimer’s Disease Agent: Targeting C/EBPβ/δ-Secretase Pathway, NSFGD, RMB 100,000.
9. PI, 基於 TREM2通路探討天麻鉤藤藥對抗阿爾茨海默病的作用機制, NSFGD, RMB 100,000.
10. PI, Preclinical Studies of Modulatory Effects of Magnolol, Honokiol and Their Combination on Neurocognitive Dysfunction and Beta Amyloid Associated-Neuropathology: Exploring Its Therapeutic Potential for Alzheimer’s Disease, Direct Grant, HK$ 143,000
11. PI, Probing Nanoparticle Rhynchophylline as a Novel Anti-Alzheimer’s Disease Agent: Efficacy and Action Mechanism in 3xTg-AD Transgenic Mouse, Direct Grant, HK$ 64,260
12. PI, 進行探討眠樂改良方及臨床經驗中藥複方對小鼠的鎮靜催眠作用研究, Research Contract Agreement, HK$ 225,000
13. PI, 香港中藥市場調研及新產品對策研究, Service Agreement, RMB 180,000

Co-Investigator:

1. Co-I, Costunolide Overcomes Gemcitabine Resistance in Pancreatic Cancer by Inhibiting FAM198B Expression, RGC/GRF, HK$ 1,381,520
2. Co-I, Bile acid metabolite ursodeoxycholic acid modulates antitumour immunity in pancreatic adenocarcinoma, RGC/GRF, HK$ 1,208,830
3. Co-I, Chinese Medicine Innotech Limited, ITC (TSSSU-O), HK$ 400,000
4. Co-I, Modified Huang-Lian-Jie-Du Decoction for the Treatment of Atopic Dermatitis: A Randomized Placebo-Controlled Trial on Its Efficacy and Impact on Gut Microbiome, HMRF, HK$1,431,942
5. Co-I,《中醫藥應對新型冠狀病毒病指南》書籍出版, Chinese Medicine Development Fund (CMDF), HK$468,150
6. Co-I, Modified Gan-Mai-Da-Zao Decoction for the Treatment of Behavioral and Psychological Symptoms of Dementia: Preclinical Evaluations on Its Efficacy, Safety and Molecular Mechanisms, HMRF, HK$1,193,424
7. Co-I, 基於Nrf2信號通路探討鴉膽子活性成分對胰腺癌化療敏感性的影響及機制研究, NSFC, RMB 550,000
8. Co-I, Yunzhi Essence Improves the Quality of Life of Patients with Advanced Cancer: A Randomized, Double-blinded, Placebo-controlled Trial, ITF, HK$ 1,554,581.26
9. Co-I, Development of A Chinese Medicine Formula as a Novel Anti-Alzheimer’s Disease Agent: In Vivo Evaluation on Its Efficacy, Safety and Action Mechanisms, ITF, HK$ 1,397,342
10. Co-I, Clinical Safety, Efficacy and Multiomic Evaluation of a Novel Chinese Medicine (CM) Formula in Type 2 Diabetes (T2D): Effects on Beta-Cell Function And Insulin Resistance, ITF, HK$ 4,966,735
11. Co-I, Development of a Novel Chinese Medicine Formula for the Treatment of Psoriasis: Preclinical Studies on Its Efficacy and Safety and A Randomized, Double-blinded, Placebo-controlled Trial, ITF, HK$ 3,996,342
12. Co-I, Development of Modified Huang-Lian-Jie-Du Decoction as an Innovative Anti-Atopic Dermatitis Preparation: In Vivo Evaluation on Its Efficacy, Safety and Action Mechanisms, ITF, HK$ 1,181,717
13. Co-I, Efficacy of Uncaria Rhynchophylla (Gou-Teng) for Patients with Mild Cognitive Impairment: A Pilot Randomized Controlled Trial Using White Matter Hyperintensities Estimated by ARIA as Outcome, HMRF, HK$ 941,780
14. Co-I, 基於Keap1-Nrf2/NF-κB通路平衡體系研究廣藿香活性成分抗急性肺損傷的作用機制, NSFC, RMB 240,000
15. Co-I, Development of a Novel Chinese Medicine Formula for the Treatment of Gout: Preclinical Evaluation on Its Efficacy, Safety and Molecular Mechanisms, Peter Hung Pain Research Institute (PHPRI) research Grant, HK$ 1,500,000
16. Co-I, Development of an Aphrodisiac Chinese Medicine Formula: Studies on Animal Models of Erectile Dysfunction and Premature Ejaculation, Research Contract Agreement, HK$ 1,500,000